Adagene Inc. (ADAG)
$1.3
Rating:
Recommendation:
-
| Symbol | ADAG |
|---|---|
| Price | $1.3 |
| Beta | 0.175 |
| Volume Avg. | 0.02M |
| Market Cap | 56.985M |
| Shares () | - |
| 52 Week Range | 0.9-2.1 |
| 1y Target Est | - |
| DCF Unlevered | ADAG DCF -> | |
|---|---|---|
| DCF Levered | ADAG LDCF -> | |
| ROE | -66.74% | Strong Sell |
| ROA | -52.48% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 33.66% | Neutral |
| P/E | -1.48 | Sell |
| P/B | 0.85 | Buy |
Latest ADAG news
About
Download (Excel)Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.